Cepheid Gets Health Canada License For Four-in-one Rapid Molecular Diagnostic Test WASHINGTON (dpa-AFX) - Cepheid, a unit of Danaher Corp. (DHR), said Thursday that it has received a medical device license from Health Canada for Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and RSV infections from a single patient sample. The test is now available in Canada and can be used in laboratories and at the point of care. Cepheid noted that the four-in-one test is designed for use on any of the company's almost 30,000 GeneXpert Systems placed worldwide, with results delivered in approximately 36 minutes.